Clinical Trial Update: Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of AVE1642 in combination with fulvestrant for advanced hormone-dependent breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AVE1642
• Faslodex (fulvestrant)

Snippet

Sponsor: Sanofi | Conditions: Breast Neoplasms | Phase 2 | Status: TERMINATED